Stock Report

All about this stock under one free report Last Updated: 30-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Ranbaxy Lab Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: RANBAXY | BSE: 500359

₹859.80

up-down-arrow ₹45.80 (5.63%)

As on 01-Apr-2015IST

Market cap

info icon

₹36,603 Cr

Revenue (TTM)

info icon

₹5,759 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

14

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -23.43 -26.10 2.61 -- --
EBIT -72.97 -123.06 78.63 -- --
Net Profit -285.73 -258.74 92.36 -- --
EPS -285.20 -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-14Mar-13
EBIT-Margin info -----2.953.75--
Net Margin info -----2.08-7.98--
Return on equity info -----10.47-29.26--
Return on Capital info -------1.95--
Return on Assets info -----2.06-7.08--
Debt to Equity (x) info ----1.322.01--

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
-4.30
2.04
-35.14
19.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-10.47

Lower than Peers by 21.33

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
-10.47
-59.07
-8.52
-86.78
25.32
Peer Median
10.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-2.06

Lower than Peers by 8.80

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
-2.06
-5.98
-1.09
-21.20
9.42
Peer Median
6.74
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-2.95

Lower than Peers by 15.64

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
-2.95
-8.81
4.07
10.26
17.66
Peer Median
12.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-2.08

Lower than Peers by 10.94

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
-2.08
-11.49
-2.47
-38.05
19.04
Peer Median
8.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
-8.67
0.38
-35.53
24.21
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

2.61

Lower than Peers by 5.53

Year on year growth in net sales

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
2.61
8.91
-19.18
37.56
18.60
Peer Median
8.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

78.63

Higher than Peers by 61.38

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
78.63
--
-67.90
-20.12
101.65
Peer Median
17.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

92.36

Higher than Peers by 75.51

Year on year growth in profit after tax

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
92.36
-441.46
94.68
-365.69
100.83
Peer Median
16.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

92.61

Higher than Peers by 82.01

Year on year growth in earnings per share

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
92.61
-440.93
94.69
-365.08
100.54
Peer Median
10.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
-43.38
-0.64
-62.66
29.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

1.32

Higher than Peers by 1.27

Total debt / Net worth

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
1.32
5.75
2.53
2.27
0.83
Peer Median
0.04
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

2.50

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
2.50
3.21
1.46
1.52
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.61

Lower than Peers by 1.11

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
0.61
0.65
0.87
0.82
1.93
Peer Median
1.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.46

Lower than Peers by 0.71

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
0.46
0.48
0.67
0.65
1.59
Peer Median
1.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

3.70

Lower than Peers by 4.17

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
3.70
-0.55
0.45
-9.20
29.88
Peer Median
7.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

41.76

Higher than Peers by 15.97

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
41.76
18.03
22.78
47.22
22.80
Peer Median
25.79
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.87

Higher than Peers by 0.21

Sales / Average Total Assets

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
0.87
0.47
0.43
0.54
0.47
Peer Median
0.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
70.62
147.54
116.14
90.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
90.52
97.63
73.42
87.29
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
53.65
70.24
82.17
85.46
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
107.49
174.93
107.39
92.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
--
--
--
21.94
Peer Median
39.90
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

13.98

Higher than Peers by 9.75

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
13.98
14.36
11.19
8.94
4.92
Peer Median
4.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
--
--
--
--
0.33
Peer Median
0.10
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

36.82

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
36.82
45.28
33.19
15.04
16.79
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

36,603

Higher than Peers by 28,990

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-14
Dec-12
Dec-11
Dec-10
Ranbaxy Lab
36,603
15,453
21,262
17,102
25,206
Peer Median
7,613
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...